Cocrystal Pharma (COCP) Competitors $1.43 -0.15 (-9.49%) Closing price 04:00 PM EasternExtended Trading$1.36 -0.07 (-4.90%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock COCP vs. IZTC, CUE, HOWL, DRRX, ICCC, PDSB, DTIL, ATNM, INMB, and IMAShould you be buying Cocrystal Pharma stock or one of its competitors? The main competitors of Cocrystal Pharma include Invizyne Technologies (IZTC), Cue Biopharma (CUE), Werewolf Therapeutics (HOWL), DURECT (DRRX), ImmuCell (ICCC), PDS Biotechnology (PDSB), Precision BioSciences (DTIL), Actinium Pharmaceuticals (ATNM), INmune Bio (INMB), and ImageneBio (IMA). These companies are all part of the "pharmaceutical products" industry. Cocrystal Pharma vs. Its Competitors Invizyne Technologies Cue Biopharma Werewolf Therapeutics DURECT ImmuCell PDS Biotechnology Precision BioSciences Actinium Pharmaceuticals INmune Bio ImageneBio Invizyne Technologies (NASDAQ:IZTC) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations. Do institutionals and insiders believe in IZTC or COCP? 6.7% of Cocrystal Pharma shares are held by institutional investors. 28.1% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has higher valuation & earnings, IZTC or COCP? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvizyne TechnologiesN/AN/AN/AN/AN/ACocrystal PharmaN/AN/A-$17.50M-$1.24-1.15 Do analysts recommend IZTC or COCP? Cocrystal Pharma has a consensus price target of $6.00, suggesting a potential upside of 319.58%. Given Cocrystal Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Cocrystal Pharma is more favorable than Invizyne Technologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cocrystal Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IZTC or COCP more profitable? Invizyne Technologies' return on equity of 0.00% beat Cocrystal Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Invizyne TechnologiesN/A N/A N/A Cocrystal Pharma N/A -144.12%-102.85% Does the media prefer IZTC or COCP? In the previous week, Cocrystal Pharma had 6 more articles in the media than Invizyne Technologies. MarketBeat recorded 8 mentions for Cocrystal Pharma and 2 mentions for Invizyne Technologies. Invizyne Technologies' average media sentiment score of 0.37 beat Cocrystal Pharma's score of 0.13 indicating that Invizyne Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invizyne Technologies 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cocrystal Pharma 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryCocrystal Pharma beats Invizyne Technologies on 6 of the 9 factors compared between the two stocks. Get Cocrystal Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COCP vs. The Competition Export to ExcelMetricCocrystal PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.21M$3.15B$5.78B$10.19BDividend YieldN/A2.33%5.73%4.61%P/E Ratio-1.1521.2474.8626.40Price / SalesN/A467.56543.78125.99Price / CashN/A44.4425.8129.91Price / Book1.529.6413.256.28Net Income-$17.50M-$53.20M$3.29B$270.38M7 Day Performance-4.67%0.44%0.47%2.70%1 Month Performance-15.63%4.26%4.60%5.99%1 Year Performance-14.37%9.43%73.42%25.94% Cocrystal Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COCPCocrystal Pharma2.2532 of 5 stars$1.43-9.5%$6.00+319.6%-5.4%$16.21MN/A-1.1510News CoverageShort Interest ↑Gap DownIZTCInvizyne TechnologiesN/A$9.70flatN/AN/A$60.64MN/A0.0029Gap UpCUECue Biopharma2.46 of 5 stars$0.78-2.7%N/A+25.9%$59.96M$9.29M-1.3960Positive NewsHOWLWerewolf Therapeutics4.0065 of 5 stars$1.31-5.8%$8.00+510.7%-38.9%$59.90M$1.88M-0.8040DRRXDURECT1.5165 of 5 stars$1.92-1.0%N/AN/A$59.62M$2.03M-19.2080Short Interest ↓ICCCImmuCell1.4895 of 5 stars$6.40+4.6%N/A+63.1%$57.89M$26.49M33.6970Positive NewsPDSBPDS Biotechnology2.346 of 5 stars$1.24flat$10.00+706.5%-61.3%$57.83MN/A-1.3520Positive NewsDTILPrecision BioSciences4.094 of 5 stars$4.90-2.4%$47.00+859.2%-55.2%$57.76M$68.70M-0.56200ATNMActinium Pharmaceuticals2.2103 of 5 stars$1.78+2.3%$4.50+152.8%-12.4%$55.53MN/A-1.2830INMBINmune Bio3.1492 of 5 stars$2.03-2.9%$18.40+806.4%-63.2%$53.97M$10K-0.8210News CoverageShort Interest ↓IMAImageneBio3.3387 of 5 stars$13.40-0.4%$35.50+164.9%-54.9%$53.87M$9.16M-1.7470Positive NewsGap Down Related Companies and Tools Related Companies IZTC Competitors CUE Competitors HOWL Competitors DRRX Competitors ICCC Competitors PDSB Competitors DTIL Competitors ATNM Competitors INMB Competitors IMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:COCP) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cocrystal Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cocrystal Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free COCP Stock Alerts